Division of Becton Dickinson & Co.
Latest From BD Biosciences
Another busy time for executive moves in the Asia Pacific region, as Amgen China GM joins Henlius, BeiGene appoints new immuno-oncology CMO and Sumitomo Dainippon names a new digital health head. Changes also take place at Ascentage, Harbin Pharma and AdvaMed.
Brazil has passed legislation enabling class I (lowest risk) devices and diagnostics to gain market approval through a notification pathway rather than under the current review-based registration system. The move is essentially intended to help regulatory agency Anvisa refocus its efforts toward the higher-risk arena.
The group that helped developed a framework to incorporate patient preference data into regulatory device submissions has released a new document to help in vitro diagnostics sponsors tackle the problem of limited sampling by using surrogate samples. The plan has been reviewed by top FDA officials.
Becton Dickinson President, Chairman and CEO Vincent Forlenza speaks to IN VIVO about the business prospects at Becton Dickinson as it integrates its major acquisition, CareFusion, and oversees a major internal group restructuring, and about his role as the current chairman of AdvaMed.
Drug Discovery Tools
- Drug Discovery Tools
- Research, Analytical Equipment & Supplies
- Therapeutic Areas
- North America
- Parent & Subsidiaries
- Becton Dickinson & Co.
- Senior Management
- Alberto Mas, Pres.
- Contact Info
Phone: (877) 232-8995
2350 Qume Dr.
San Jose, CA 95131
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.